Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SAN CARLOS, Calif., Nov. 13, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Chief Financial Officer, Timothy Morris, will present a Company overview and pipeline update at the Jefferies 2017 London Healthcare Conference on Thursday, November 16, 2017 at 10:00 a.m. GMT in London, United Kingdom.
A live audio webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcast will be archived on Iovance Biotherapeutics’ website for 30 days following the presentation.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Relations Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
[email protected]
[email protected]
